Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas

International Journal of Cancer

Volumn 105, Issue 2, 2003, Pages 190-195

  Dannenberg, Hilde ^a   De Krijger, Ronald R ^a   Van der Harst, Erwin ^b   Abbou, Mustaffa ^a   Ijzendoorn, Ynske ^a   Komminoth, Paul ^c   Dinjens, Winand N M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Hospital Baden   (Switzerland)

Author keywords

Loss of heterozygosity; Mutation; Pheochromocytoma; Von Hippel Lindau

Indexed keywords

GENE PRODUCT;

ARTICLE; CANCER SUSCEPTIBILITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 3; DNA; EXONS; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; GENOTYPE; GERM-LINE MUTATION; HIPPEL-LINDAU DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; LIGASES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037431550     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11060     Document Type: Article

References (47)

1. Maher ER, Kaelin WG Jr. Von Hippel-Lindau disease. Medicine (Balt) 1997;76:381-91.
2. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
3. Vortmeyer AO, Huang SC, Pack SD, Koch CA, Lubensky IA, Oldfield EH, Zhuang Z. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 2002;21:1167-70.
4. Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-601.
5. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
6. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998;95:993-8.
7. Pause A, Peterson B, Schaffar G, Stearman R, Klausner RD. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 1999;96:9533-8.
8. de Paulsen N, Brychzy A, Fournier MC, Klausner RD, Gnarra JR, Pause A, Lee S. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387-92.
9. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25.
10. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, Baylin SB. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
11. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998;243:541-5.
12. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 1998;63:1025-35.
13. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia Y, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
14. Stebbins CE, Kaelin WG Jr., Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999;284:455-61.
15. Morikawa T, Suzuki M, Unno M, Endo K, Katayose Y, Matsuno S. Malignant pheochromocytoma with hepatic metastasis diagnosed 10 years after a resection of the primary incidentaloma adrenal lesion: report of a case. Surg Today 2001;31:80-4.
16. Tippett PA, West RS, McEwan AJ, Middleton JE, Ackery DM. A comparison of dopamine and homovanillic acid excretion, as prognostic indicators in malignant phaeochromocytoma. Clin Chim Acta 1987;166:123-33.
17. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989;7:1720-5.
18. Nativ O, Grant CS, Sheps SG, O'Fallon JR, Farrow GM, van Heerden JA, Lieber MM. Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern. J Surg Oncol 1992;50:258-62.
19. Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 1998;82:176-9.
20. van der Harst E, de Krijger RR, Bruining HA, Lamberts SW, Bonjer HJ, Dinjes WN, Proye C, Koper JW, Bosman FT, Roth J, Heitz PU, Komminoth P. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 1998;79:537-40.
21. de Krijger RR, van der Harst E, van der Ham F, Stünen T, Dinjens WN, Koper JW, Bruining HA, Lamberts SW, Bosman FT. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 1999;188:51-5.
22. van der Harst E, Bruining HA, Jaap Bonjer H, van der Ham F, Dinjens WN, Lamberts SW, de Herder WW, Koper JW, Stijnen T, Proye C, Lecomte-Houcke M, Bosman FT, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 2000;191:175-80.
23. Dannenberg H, Speel EJ, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi WJ, Komminoth P, de Krijger RR. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 2000;157:353-9.
24. Gupta D, Shidham V, Holden J, Layfield L, Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol 2000;8:267-74.
25. Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri AI, Heikkila P, Liu J. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001;86:2231-5.
26. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
27. Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D, Bornstein SR, Chrousos GP, Pacak K. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 2002;146:381-8.
28. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
29. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000;60:6822-5.
30. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49-54.
31. Aguiar RC, Cox G, Pomeroy SL, Dahia PL. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGLI), in pheochromocytomas. J Clin Endocrinol Metab 2001;86:2890-4.
32. Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PL, O'Riordan JL, Toledo SP, Smith DP, Maher ER, et al. Mutations in the RET proto-oncogene and the von HippelLindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995;32:934-7.
33. Hofstra RM, Stelwagen T, Stulp RP, de Jong D, Hulsbeek M, Kamsteeg EJ, van den Berg A, Landsvater RM, Vermey A, Molenaar WM, Lips CJ, Buys CH. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 1996;81:2881-4.
34. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, Neumann HP. Differential genetic alterations in von Hippel-Lindau Syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 2000;85:4568-74.
35. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000;60:1942-8.
36. Koch CA, Huang SC, Zhuang Z, Stolle C, Azumi N, Chrousos GP, Vortmeyer AO, Pacak K. Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene 2002;21:479-82.
37. van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW, Koper JW. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 1998;77:337-40.
38. Bot FJ, Sleddens HF, Dinjens WN. Molecular assessment of clonality leads to the identificafion of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma. Diagn Mol Pathol 1998;7:295-301.
39. Wijnhoven BP, Lindstedt EW, Abbou M, IJzendoorn Y, de Krijger RR, Tilanus HW, Dinjens WN. Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor γ tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction. Int J Cancer 2001;94:891-5.
40. Bradley JF, Rothberg PG. Processed pseudogene from the von Hippel-Lindau disease gene is located on human chromosome 1. Diagn Mol Pathol 1999;8:101-6.
41. Frischmeyer PA, van Hoof A, O'DonnelI K, Guerrerio AL, Parker R, Dietz HC. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002;295:2258-61.
42. Cassan M, Rousset JP. UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals. BMC Mol Biol 2001;2:3.
43. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-71.
44. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993;329:1531-8.
45. Wilson RA, Ibanez ML. A comparative study of 14 cases of familial and nonfamilial pheochromocytomas. Hum Pathol 1978;9:181-8.
46. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001;21:865-74.
47. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-27.